Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
S Bowyer, P Prithviraj, P Lorigan, J Larkin, G McArthur, V Atkinson, M Millward, M Khou, Stefan Diem, S Ramanujam, B Kong, E Liniker, A Guminski, P Parente, M C Andrews, S Parakh, J Cebon, G V Long, M S Carlino & O Klein
Ipilimumab therapy can induce responses in patients who fail the anti-PD-1 therapy with response rates comparable to previous reports. There appears to be an increased frequency of high-grade immune-related adverse events including pneumonitis that warrants close surveillance.
|citation||Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews M C, Parakh S, Cebon J, Long G V, Carlino M S, Klein O. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br J Cancer 2016; 114:1084-9.|
|type||journal paper/review (English)|
|date of publishing||28-04-2016|
|journal title||Br J Cancer (114/10)|